par Piccart-Gebhart, Martine 
;Procter, Marion;Leyland-Jones, Brian;Goldhirsch, Aron;Untch, M.;Smith, Ian;Gianni, L.;Baselga, J;Bell, Richard H;Jackisch, C.;Cameron, David A;Dowsett, Mitch;Barrios, CH;Steger, G.;Huang, C.-S.;Andersson, Michael;Inbar, M.;Lichinitser, Michail;Lang, Istvan;Nitz, U.;Iwata, Hiroji;Thomssen, C.;Lohrisch, C;Suter, T.;Rüschoff, Josef;Sütö, T.;Greatorex, V.;Ward, David;Straehle, Carolyn;McFadden, E.;Dolci, Stella;Gelber, R D;HERA study team,
Référence The New England journal of medicine, 353, 16, page (1659-1672)
Publication Publié, 2005-10
;Procter, Marion;Leyland-Jones, Brian;Goldhirsch, Aron;Untch, M.;Smith, Ian;Gianni, L.;Baselga, J;Bell, Richard H;Jackisch, C.;Cameron, David A;Dowsett, Mitch;Barrios, CH;Steger, G.;Huang, C.-S.;Andersson, Michael;Inbar, M.;Lichinitser, Michail;Lang, Istvan;Nitz, U.;Iwata, Hiroji;Thomssen, C.;Lohrisch, C;Suter, T.;Rüschoff, Josef;Sütö, T.;Greatorex, V.;Ward, David;Straehle, Carolyn;McFadden, E.;Dolci, Stella;Gelber, R D;HERA study team, Référence The New England journal of medicine, 353, 16, page (1659-1672)
Publication Publié, 2005-10
Article révisé par les pairs
| Titre: |
|
| Auteur: | Piccart-Gebhart, Martine; Procter, Marion; Leyland-Jones, Brian; Goldhirsch, Aron; Untch, M.; Smith, Ian; Gianni, L.; Baselga, J; Bell, Richard H; Jackisch, C.; Cameron, David A; Dowsett, Mitch; Barrios, CH; Steger, G.; Huang, C.-S.; Andersson, Michael; Inbar, M.; Lichinitser, Michail; Lang, Istvan; Nitz, U.; Iwata, Hiroji; Thomssen, C.; Lohrisch, C; Suter, T.; Rüschoff, Josef; Sütö, T.; Greatorex, V.; Ward, David; Straehle, Carolyn; McFadden, E.; Dolci, Stella; Gelber, R D; HERA study team, |
| Informations sur la publication: | The New England journal of medicine, 353, 16, page (1659-1672) |
| Statut de publication: | Publié, 2005-10 |
| Sujet CREF: | Sciences bio-médicales et agricoles |
| MeSH keywords: | Adult |
| Antibodies, Monoclonal -- adverse effects | |
| Antibodies, Monoclonal -- therapeutic use | |
| Antineoplastic Agents -- adverse effects | |
| Antineoplastic Agents -- therapeutic use | |
| Breast Neoplasms -- drug therapy | |
| Breast Neoplasms -- mortality | |
| Breast Neoplasms -- radiotherapy | |
| Breast Neoplasms -- surgery | |
| Chemotherapy, Adjuvant | |
| Combined Modality Therapy | |
| Disease-Free Survival | |
| Female | |
| Heart Diseases -- chemically induced | |
| Humans | |
| Middle Aged | |
| Receptor, erbB-2 -- analysis | |
| Recurrence | |
| Survival Analysis | |
| Note générale: | Clinical Trial |
| Clinical Trial, Phase III | |
| Comparative Study | |
| Journal Article | |
| Multicenter Study | |
| Randomized Controlled Trial | |
| Research Support, Non-U.S. Gov't | |
| Langue: | Anglais |
| Identificateurs: | urn:issn:0028-4793 |
| info:doi/10.1056/NEJMoa052306 | |
| info:pii/353/16/1659 | |
| info:scp/26844503270 | |
| info:pmid/16236737 |
